Zinc’s Association with the CmPn/CmP Signaling Network in Breast Cancer Tumorigenesis
Open Access
- 11 November 2022
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 12 (11) , 1672
Abstract
It is well-known that serum and cellular concentrations of zinc are altered in breast cancer patients. Specifically, there are notable zinc hyper-aggregates in breast tumor cells when compared to normal mammary epithelial cells. However, the mechanisms responsible for zinc accumulation and the consequences of zinc dysregulation are poorly understood. In this review, we detailed cellular zinc regulation/dysregulation under the influence of varying levels of sex steroids and breast cancer tumorigenesis to try to better understand the intricate relationship between these factors based on our current understanding of the CmPn/CmP signaling network. We also made some efforts to propose a relationship between zinc signaling and the CmPn/CmP signaling network.Keywords
This publication has 141 references indexed in Scilit:
- The biology of progesterone receptor in the normal mammary gland and in breast cancerMolecular and Cellular Endocrinology, 2012
- Dietary zinc deficiency fuels esophageal cancer development by inducing a distinct inflammatory signatureOncogene, 2011
- Zinc availability regulates exit from meiosis in maturing mammalian oocytesNature Chemical Biology, 2010
- Zinc Released from Injured Cells Is Acting via the Zn2+-sensing Receptor, ZnR, to Trigger Signaling Leading to Epithelial RepairJournal of Biological Chemistry, 2010
- Cell-Nonautonomous Regulation of C. elegans Germ Cell Death by kri-1Current Biology, 2010
- The important role of the apoptotic effects of zinc in the development of cancersJournal of Cellular Biochemistry, 2009
- Prevention of upper aerodigestive tract cancer in zinc‐deficient rodents: Inefficacy of genetic or pharmacological disruption of COX‐2International Journal of Cancer, 2007
- Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotypeCancer, 2007
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006
- Expression levels of the putative zinc transporter LIV‐1 are associated with a better outcome of breast cancer patientsInternational Journal of Cancer, 2005